Beyond the GLP-1 Boom: Devices, Diagnostics, and Manufacturing in the New Obesity Economy

GLP-1 therapies have quickly changed the obesity and cardiometabolic care landscape but the impact is no longer limited to pharma pipelines. As these therapies expand across obesity, diabetes, cardiovascular risk, sleep apnea, liver disease, kidney disease, and long-term chronic care, the second-order effects are showing up across devices, diagnostics, manufacturing, supply chain, and patient support.

For strategy and corporate development leaders, the key question is how to read the market early. Which categories gain momentum, which face disruption, and where should companies reposition portfolio, capital, and partnerships before the shift becomes obvious?

This panel will explore how the obesity treatment wave is influencing drug delivery platforms, autoinjectors, oral formulations, patient monitoring, diagnostic testing, CDMO capacity, fill-finish infrastructure, packaging, and commercial strategy across the healthcare ecosystem.

What attendees will learn

• How GLP-1 growth is affecting demand for pens, autoinjectors, connected devices, adherence tools, and patient support models.
• Where diagnostics and monitoring may play a larger role in metabolic, liver, kidney, cardiovascular, and sleep-related care.
• How oral GLP-1s and next-generation formulations could change device and manufacturing needs.
• Why manufacturing capacity, fill-finish, packaging, and supply chain strategy are becoming key competitive factors.
• Where medtech, diagnostics, life science tools, and CDMO companies may find new growth, partnership, or market-entry opportunities.
• How leading companies are pressure-testing portfolio strategy against a fast-moving demand shift.